Moxclav 156.25mg Syrup

In multidrug-resistant (MDR) tuberculosis, the causative bacteria produce an enzyme called beta-lactamase. This enzyme breaks down the antibiotics and makes them ineffective. As a result, the bacteria become resistant to the antibiotic being used for treatment. Moxclav 156.25mg Syrup comprises two active ingredients, amoxycillin and clavulanic acid. While clavulanic acid stops the enzyme from rendering amoxycillin ineffective, amoxycillin works towards killing the tuberculosis-causing bacteria. This makes the combination of amoxycillin and clavulanic acid an effective treatment for resistant tuberculosis.